Recent Research Analysts’ Ratings Changes for Astrazeneca (AZN)

A number of research firms have changed their ratings and price targets for Astrazeneca (NYSE: AZN):

• 7/13/2026 – Astrazeneca was downgraded by HSBC Holdings plc from “buy” to “hold”.
• 7/1/2026 – Astrazeneca had its “buy” rating reaffirmed by Bank of America Corporation.
• 7/1/2026 – Astrazeneca had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc..
• 6/30/2026 – Astrazeneca had its “buy” rating reaffirmed by JPMorgan Chase & Co..
• 6/30/2026 – Astrazeneca had its “sell” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 6/26/2026 – Astrazeneca had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 6/18/2026 – Astrazeneca was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 6/9/2026 – Astrazeneca had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 6/9/2026 – Astrazeneca had its “sell” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 6/9/2026 – Astrazeneca had its “buy” rating reaffirmed by JPMorgan Chase & Co..
• 6/8/2026 – Astrazeneca had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 6/1/2026 – Astrazeneca had its “buy” rating reaffirmed by JPMorgan Chase & Co..
• 6/1/2026 – Astrazeneca had its “buy” rating reaffirmed by Barclays PLC.
• 5/21/2026 – Astrazeneca had its “sell” rating reaffirmed by Deutsche Bank Aktiengesellschaft.

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.